“…Introduction. Unlike hormonal contraception (e.g., testosterone), which exerts its effects to disrupt the hypothalamic-pituitary-testicular axis (Page et al, 2008;Huhtaniemi, 2010;Wang and Swerdloff, 2010), or approaches that target the epididymis (O'Rand et al, 2007;Blithe, 2008;Kopf, 2008;Mruk, 2008;Sipilä et al, 2009), the development of nonhormonal male contraceptives, such as adjudin Cheng and Mruk, 2010b), bisdichloroacetyldiamines (Hogarth and Griswold, 2010;Amory et al, 2011;Hogarth et al, 2011), gamendazole (Tash et al, 2008a,b), indenopyridine 5SR,3,4,4a,5,-1H-indeno-[1,2-c]-pyridine-hydrochloride, also known as RTI-4587-073) (Hild et al, 2004(Hild et al, , 2007aKoduri et al, 2008), and immunological approaches that target sperm-specific postmeiotic germ cell antigens (Suri, 2005;Mruk, 2008;McLaughlin and Aitken, 2011), requires a better understanding of the BTB because these compounds exert their effects, at least in part, behind the BTB in the apical compartment of the seminiferous epithelium Cheng and Mruk, 2010b;Mok et al, 2011b). As described above, the BTB largely dictates how much drug can enter the apical compartment of the seminiferous epithelium to exert its effects behind the immunological barrier.…”